Compare Charles River Laboratories Intl. Inc (CRL) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Intel Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Intel Corp trades at $101.26 (market cap $492.85B). The key difference: Intel Corp is far larger — about 36.6× Charles River Laboratories Intl. Inc's market cap, and Intel Corp pays a 2.24% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | INTC | |
|---|---|---|
Market Cap | $13.46B | $492.85B |
Sector | Health | Technology |
52-Week High | $282.00 | $140.94 |
52-Week Low | $145.57 | $21.81 |
Enterprise Value | $16.30B | $513.66B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Intel (INTC) trades at $102.74, up 5.35% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats in Q1 and Q2 2026 highlight improving operational performance, though net income remains negative. The company is raising $20 billion via a stock offering to fund AI and foundry expansion, driving investor focus on growth prospects amid margin challenges.
Outlook: Intel's revenue growth and strategic investments in AI present upside potential, but shareholder dilution from the equity raise and persistent negative margins pose risks. Analyst consensus is mixed with a $116.67 price target, suggesting cautious optimism for the turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
